Japan approves iron deficiency drug from Pharmacosmos

With the approval from the Japanese health authorities, Danish pharmaceutical firm Pharmacosmos can now initiate the launch of its iron deficiency anemia treatment in Japan.

Photo: Pharmacosmos / PR

Five years after Danish Pharmacosmos entered a strategic collaboration with Japanese partner Nippon Shinyaku on the launch of Monover (ferric derisomaltose) in Japan, the two parties can now initiate the marketing efforts in the country.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Bank believes in cancer approval for Genmab

In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.

Further reading

Related articles

Latest news

See all jobs